Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
06. März 2019 16:10 ET
|
Xeris Pharmaceuticals, Inc.
Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ Advancing pipeline of preclinical and clinical development-stage products Cash position of $112.6 million at year-end...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01. März 2019 16:15 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, March 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
20. Februar 2019 07:30 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
13. Februar 2019 19:26 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock
11. Februar 2019 16:05 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress
07. November 2018 08:00 ET
|
Xeris Pharmaceuticals, Inc.
Glucagon pen NDA accepted for review by FDA Continuing to execute commercial build and launch readiness for glucagon pen Advancing pipeline of preclinical and clinical development-stage products...
Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights
13. August 2018 08:00 ET
|
Xeris Pharmaceuticals, Inc.
Successfully Completed Initial Public Offering (IPO) Submitted New Drug Application (NDA) for Glucagon Rescue Pen CHICAGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq:...
Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences
31. Juli 2018 07:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, July 31, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team
30. Juli 2018 07:00 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, July 30, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26. Juni 2018 16:15 ET
|
Xeris Pharmaceuticals, Inc.
CHICAGO, June 26, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...